Showing results (181-190 of 225) with videos related to

Sort By:
Pageof 23
Clinical Genitourinary Cancer|May 28, 2018
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?Roberto Iacovelli, Ugo De Giorgi, Luca Galli, et al.
Annals of Surgical Oncology|December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitorsMatteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Urologic Oncology|April 3, 2019
The effect of a treatment delay on outcome in metastatic renal cell carcinomaRoberto Iacovelli, Luca Galli, Ugo De Giorgi, et al.
Targeted Oncology|August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Lancet (London, England)|September 16, 2024
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 StudyToni K Choueiri, Laurence Albiges, Philippe Barthélémy, et al.
Targeted Oncology|July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Plos One|April 18, 2015
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?Francesco Pantano, Matteo Santoni, Giuseppe Procopio, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2013
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohortRoberto Iacovelli, Giacomo Cartenì, Cora N Sternberg, et al.
JAMA Oncology|September 1, 2022
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical TrialNizar M Tannir, Neeraj Agarwal, Camillo Porta, et al.
Future Oncology (London, England)|March 20, 2014
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community settingGiuseppe Procopio, Lisa Derosa, Angela Gernone, et al.
Pageof 23